summit clinical trial tirzepatide SUMMIT: Improves Outcomes and Quality of Life For Patients With HFpEF and Obesity Tirzepatide's Surmount-4 Trial Reveals Groundbreaking

Key things they look at include: Total Cholesterol: An overview of all cholesterol in your blood

Overall, it appears that overweight, obese, and/or diabetic research subjects have better results than normal-weight subjects when using a GLP-1 medication to treat a substance use disorder (Marquez-Meneses, 2025)

Poor diet, environmental pollutants, and lack of sleep can also drain our reserves

Always discuss alternative options with your healthcare team to ensure safe and effective diabetes management tailored to your individual needs

If approved, bimagrumab would likely be reserved for people at higher risk of losing too much muscle: Older adults , where muscle loss can lead to frailty, falls, or functional decline People with very low starting muscle mass , where further loss could affect mobility or metabolic health Those on long-term GLP-1 therapy , especially at higher doses or lower food intake That said, bimagrumab could also have a role in post-weight-loss maintenance

Here's what else to expect from the GLP-1 pills, including their efficacy and availability